India: Review Of Indian Patent Law In 2008

Last Updated: 10 June 2009
Article by Swathi Sukumar and Tusha Malhotra

Published in Asialaw April 2009

2008 saw several important decisions in the area of patent law, the most hotly-debated branch of intellectual property law in India. Each passing year brings on further nuanced decisions in the area of patent law.

The landscape of decisions prior to 2008 was not particularly encouraging in respect of the grant of injunctions in patent cases. It was generally accepted that any sort of challenge to the validity of a patent would lead to the Court declining an interim injunction. The cases of Bilcare v. Amartara (2007, Delhi High Court), Bilcare v. Associated Capsule (2007, Delhi High Court), Standipack Pvt. Ltd. v. M/s Oswal Trading Co. Ltd.(2000, Delhi High Court) and Garware v. Mr. Kanoi (2006, Gujarat High Court) were among the important cases where interim injunctions were declined to patentees.

Against this backdrop, the Madras High Court decision in Bajaj Auto Ltd. v. TVS Motor Company Ltd. [2008 (36) PTC 417 (Mad)] was a refreshing change. The decision granted an interim injunction to the Plaintiff, after examining the parameters for grant of an injunction in patent infringement cases.

Bajaj Auto Limited filed a suit against TVS Motor Company Ltd for permanent injunction in respect of it registered patent titled "An improved Internal combustion engine working on a four stroke principle" under patent number 195904.

The said invention relates to combustion of lean air fuel mixture in small bore ranging from 45mm to 70 mm internal combustion engine working on 4 stroke principle. TVS Motor Company filed a counterclaim of revocation citing prior art to render Bajaj's patent invalid.

Further TVS contended that the subject matter of the patent is now in public domain as it was first registered in favour of a third party 20 years ago, and had now run its course.

The Hon'ble Madras High Court reiterated the basic principles of granting interim injunction as follows:

  1. the plaintiff must prove/show prima facie case that the patent is valid and infringed
  2. balance of convenience is in favour of plaintiff, and
  3. Irreparable loss that may be caused to the plaintiff by not granting an order of injunction.

The counsel for TVS argued that section 13(4) of the Patents Act, which provides that the grant of patent does not certify for its validity, precludes a determination that a prima facie case is made out merely because a patent has been registered. The counsel for Bajaj based his arguments on a harmonious construction of section 13 (4) and section 48 of the Patents Act, which provides for the exclusionary rights of a Patentee against third parties in respect f the patented product or process.

The Court granted Bajaj an interim injunction, holding that the classic tests for grant of an injunction were satisfied.

The Court reaffirmed the antiquated yardstick to ascertain the validity of a patent that is the 6 year rule. The rule states that if a patent is more than 6 years old and there has been actual use of the patented product or process, presumption of validity of patent must be drawn.

The court applying the test of adverse effect, held that the question of whether a patent was "obvious" will have to be decided in an appropriate manner in a full fledged trial. The Court held that at the interim stage, it is sufficient to show that the patent has prima facie novelty. In the present case the Hon'ble Court was of the view that the tests of injunction were met and therefore, an interim injunction was granted.

The Madras High Court in Mariappan v. A. R. Safiullah [2008 (38) PTC 341 (Mad.)], considered the issue of whether a patent could be considered prima facie valid, by virtue of registration under the Patents Act.

The provision in question was Section 13(4) of the Patents Act. In the facts of the case, the Plaintiff was the registered owner of the patent for "food-grade laminated paper, method and apparatus for manufacture the laminated paper".

The Plaintiff also held a design registration for the same product. The Plaintiff filed a suit for permanent injunction restraining infringement of Plaintiff's patent rights and design rights by the Defendants. The Defendants filed a counterclaim attacking the validity of the patent on the ground of lack of inventive step.

The Hon'ble Court in the present case went into the lack of inventive step and laid down principles pertaining to the patentability of new substances produced by known methods from known materials as follows:

  1. An invention consisting of the production of new substance from known materials by known methods cannot be held to be patentable subject-matter merely on the ground that the substances produced are new. This could lead to a situation where the substance produced may serve no useful purpose, in which case the inventor will have contributed nothing to the common stock of useful knowledge or of useful materials.
  2. Such an invention may, however be held to be patentable provided that the substances produced are not only new but also useful, though this is subject to the qualification that the substances produced must be truly new, as opposed to being merely additional members of a known series and that their useful qualities must be the inventor's own discovery as opposed to mere verification by him of previous predictions.
  3. Even where an invention consists of the production of further products belonging to a known series of products whose useful attributes have already been described or predicted, it may be patentable provided that the conditions for the grant of a selection patent are satisfied.

Then the Hon'ble division Bench went into the question of prima facie validity of a patent as provided under Section 13(4) of the Patents Act, 1970.

Section 13 (4) of the Patents Act, 1970 reads as follows:

"13. Search for Anticipation by previous publication and by prior claim

(1) – (3) ...

(4) The examination and investigations required under section 12 (examination of patent applications) and this section shall not be deemed in any way to warrant the validity of any patent, and no liability shall be incurred by the Central Government or any officer thereof by reason of, or in connection with, any such examination or investigation or any report or other proceedings consequent thereon."(Underlines supplied)

The rejected the principle laid down in the English case of Smith v. Gregg, where it was held that a right is not established sufficiently by the mere fact that a patent has been granted unless there is a substantial case established before the Court that there is in fact a valid patent.

The Hon'ble Court held that the fact of grant of patent is indeed a factor that ought to be given weightage while considering the Plaintiff's right to an interlocutory injunction.

The Court finally held that even though the banana leaf is a natural product, the invention on the part of the Plaintiff in using artificial laminated food-grade paper in the form of a banana leaf, with its colour and with artificial scented smell, is prima facie innovative. The Court held that in view of the patent having been granted in favour of the Plaintiff for the said product, he is entitled to protection by way of an interim injunction.

The Hon'ble Delhi High Court had the opportunity to consider the issue of territorial jurisdiction in cases of groundless threats of legal proceedings under section 106 of the Patents Act in Bata India limited v. Vitaflex Mauch GmbH (unreported).

Bata filed a suit against a German company, Vitaflex Mauch for sending a legal notice allegedly without any basis in an actionable right, under section 106 of the Patents Act, 1970.

In a decision rejecting Vitafelx's application for rejection of the Plaint, the Court held that in the case of a threats action, the forum to be considered is the place where the Plaintiff carries on business.

The Court held that the facts pleaded by Bata in the plaint to the effect that Bata carries on business which is likely to be adversely affected in the territorial jurisdiction of this Court, by the allegedly groundless threats of Vitaflex, are sufficient to invoke the territorial jurisdiction of the Delhi High Court.

The Court held that the Plaintiff is dominus litis in a suit to restrain groundless threats and has a right to file a suit where part of the cause of action arises. The Bata suit is still pending before the High Court.

However, the most talked about decision in Indian patent law in the last few years was the decision of the Delhi High Court in F. Hoffmann-la Roche Ltd., and Anr. v. Cipla Limited [2008 (37) PTC 71 (Del.)].

The suit was filed by Roche, a multinational pharmaceutical giant agsinst Cipla, an Indian company, seeking a permanent injunction restraining infringement of its patent right in a cancer-treatment drug.

The case was important in several respects. It is the first Indian case to consider the aspect of "pricing" of the drug in assessing whether an interim injunction ought to be granted in patent infringement law suits involving life-saving drugs.

The case was also important for its dilution of the "Six-year" rule. The rule states that interim injunctions ought not to be granted in cases of patent infringement where the patent in question is less than six years old.

The Roche decision held that the rule was to be seen as a rule of caution and prudence rather than a rigid, ritualistic formula of mathematical application.

The Court declined Roche an interim injunction and laid down several important principles in relation to grant of interim injunctions in infringement cases involving life-saving drugs.

A summary of the principles laid down by the decision are as follows:

(i) In patent infringement actions, the courts should follow approach indicated in American Cyanamide.

The governing principle is that the court should first consider whether, if the plaintiff were to succeed at trial, he could be adequately compensated by an award of damages for the loss sustained during the pendency of the hearing.

If damages would be adequate and the defendant is in a financial position to pay them, then no interlocutory injunction ought to be granted.

If on the contrary, it is found that the defendant could be compensated by way of damages at the final stages of the suit, and an undertaking for paying such damages would be an adequate remedy, then there would be no ground to refuse an interlocutory injunction.

If there is doubt as to adequacy of respective remedies, then the question of balance of convenience arises.

(ii) The Courts should follow a rule of caution, and not always presume that patents are valid, especially if the defendant challenges the validity of the patent.

(iii) The standard applicable to judge a defendant's challenge of a patent is whether the challenge is a genuine one, as opposed to a vexatious defense.

An interim injunction will be declined only if the challenge appears to be a genuine one.

If the balance is approximately equal, the Court may consider the relative strength of each party's case.

The Court also opined that unlike cases involving infringement in relation to products, the Courts have to tread with care in the case of pharmaceutical products and more specifically when life-saving drugs are involved. The Court declined Roche an injunction on the ground that several unidentified members of the public may suffer as a result of the injunction, as Roche's drug was priced much higher than Cipla's drug. The Court considered the fact that patients who were already being treated with Cipla's drug would be adversely affected if the injunction were to be granted.

The Court therefore held that the test of balance of convenience would have to take into account factors such as the likelihood of injury to unknown parties and the fact that there may be a risk of denial of remedies. The decision was subject to appeal proceedings, which are pending before a Hon'ble Division Bench of the Delhi High Court.

In summary, 2008 was an eventful year for patent law. The trend of declining interim injunctions to patentees continued in Roche, however the reasons for the refusal have now been better enunciated. The Roche decision also seems to have had a far-reaching impact on the pricing policy of pharmaceutical companies in developing countries. The decision has been celebrated by public-health activists. However, it has caused some concern on whether the Court can look into the issues of pricing which would effectively amount to treading into the area of compulsory licensing, a function which the Controller of Patents fulfills.

The Bajaj decision a well-reasoned exception to the line of cases declining injunctions, and offered patent-holders some respite.

The coming year will be critical as the patent decisions of this year are subject to appeal proceedings and decided. Several new issues are also being agitated before court this year such as the drug-patent linkage and border control for cases of patent infringement.


Swathi Sukumar is a Senior Associate in the Litigation Department in Anand and Anand. She graduated in 2005 with a Bachelor of Arts and Bachelor of Law (Honours) degree, from NALSAR University of Law, Hyderabad, India. She has been counsel in several important decisions of the Delhi High Court, including the first Indian decision on statutory dilution under trademark law and the first Indian decision protecting a film title as a trademark.

Swathi has authored several articles on IP law in international periodicals. Swathi has recently co-authored the India Chapter, in the Patent Litigation Reference Series, published by European Lawyer Ltd. She has also co-authored the India Chapter in the Global Patent Litigation series, published by Wolters Kluwer Law & Business in 2008.

Swathi has also assisted the Ministry of Science and Technology, Government of India in drafting the Public Funded R&D (Protection, Utilization and Regulation of Intellectual Property) Bill which is currently pending before the Indian Parliament.


Tusha Malhotra is an associate in Anand and Anand's litigation department. She graduated in 2008 with a bachelor's of science and a bachelor's of law degree from University of Delhi, Hyderabad, India. Her area of practice is general intellectual property litigation with a focus on patent and trade secret litigation.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions